Drug resistance in drug-resistant tuberculosis patients with and without diabetes mellitus: a comparative analysis.
Humans
Tuberculosis, Multidrug-Resistant
/ drug therapy
Male
Female
Middle Aged
Adult
Antitubercular Agents
/ therapeutic use
Risk Factors
Mycobacterium tuberculosis
/ drug effects
China
/ epidemiology
Aged
Diabetes Mellitus, Type 2
/ complications
Drug Resistance, Multiple, Bacterial
Retrospective Studies
Microbial Sensitivity Tests
Diabetes mellitus
Drug resistance profile
Drug-resistant tuberculosis
Multidrug-resistant tuberculosis
Risk factors
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
09 Aug 2024
09 Aug 2024
Historique:
received:
28
03
2024
accepted:
02
08
2024
medline:
10
8
2024
pubmed:
10
8
2024
entrez:
9
8
2024
Statut:
epublish
Résumé
This dual burden of tuberculosis (TB) and diabetes mellitus (DM) has become a global public health concern. This study aims to compare drug resistance in drug-resistant tuberculosis (DR-TB) patients with and without DM and analyse the risk factors of multidrug-resistant tuberculosis (MDR-TB). A total of 893 DR-TB patients were admitted to Wenzhou Central Hospital between January 2018 and December 2022. After excluding 178 cases with incomplete clinical and laboratory data, 715 patients were included in the study. These patients were then categorized into two groups based on the presence of type 2 DM: the DM group (160 cases) and the non-DM group (555 cases). Demographic information, baseline clinical characteristics, laboratory and imaging test results, clinical diagnoses, and other relevant data were collected for analysis. Statistical analysis was conducted on demographic information, clinical parameters, drug resistance spectrum, and risk factors for multidrug resistance. In both the DM and non-DM groups, the order of resistance to first-line anti-tuberculosis drugs is isoniazid, streptomycin, rifampicin, and ethambutol. There is no significant difference in the proportion of mono-resistant tuberculosis, polydrug-resistant tuberculosis, and multidrug-resistant tuberculosis between the two groups (P > 0.05). The prevalence of MDR-TB in both groups shows a downward trend between 2018 and 2022, but the trend is not statistically significant (P > 0.05). Among patients without DM, residence in rural areas, retreatment of tuberculosis, pulmonary cavity, and uric acid ≥ 346 µmol/L are identified as independent risk factors for MDR-TB. Among patients with DM, residence in rural areas, retreatment of tuberculosis, pulmonary cavity, and HbA1c ≥ 9.8% were identified as independent risk factors for MDR-TB. Isoniazid is the most resistant drug among DR-TB patients with and without DM. There is no statistically significant difference in drug resistance patterns between the two groups. Some progress has been made in the prevention and control of DR-TB in this area, but the effect is not very significant. There are differences in the risk factors of MDR-TB between patients with and without DM.
Sections du résumé
BACKGROUND
BACKGROUND
This dual burden of tuberculosis (TB) and diabetes mellitus (DM) has become a global public health concern. This study aims to compare drug resistance in drug-resistant tuberculosis (DR-TB) patients with and without DM and analyse the risk factors of multidrug-resistant tuberculosis (MDR-TB).
METHODS
METHODS
A total of 893 DR-TB patients were admitted to Wenzhou Central Hospital between January 2018 and December 2022. After excluding 178 cases with incomplete clinical and laboratory data, 715 patients were included in the study. These patients were then categorized into two groups based on the presence of type 2 DM: the DM group (160 cases) and the non-DM group (555 cases). Demographic information, baseline clinical characteristics, laboratory and imaging test results, clinical diagnoses, and other relevant data were collected for analysis. Statistical analysis was conducted on demographic information, clinical parameters, drug resistance spectrum, and risk factors for multidrug resistance.
RESULTS
RESULTS
In both the DM and non-DM groups, the order of resistance to first-line anti-tuberculosis drugs is isoniazid, streptomycin, rifampicin, and ethambutol. There is no significant difference in the proportion of mono-resistant tuberculosis, polydrug-resistant tuberculosis, and multidrug-resistant tuberculosis between the two groups (P > 0.05). The prevalence of MDR-TB in both groups shows a downward trend between 2018 and 2022, but the trend is not statistically significant (P > 0.05). Among patients without DM, residence in rural areas, retreatment of tuberculosis, pulmonary cavity, and uric acid ≥ 346 µmol/L are identified as independent risk factors for MDR-TB. Among patients with DM, residence in rural areas, retreatment of tuberculosis, pulmonary cavity, and HbA1c ≥ 9.8% were identified as independent risk factors for MDR-TB.
CONCLUSION
CONCLUSIONS
Isoniazid is the most resistant drug among DR-TB patients with and without DM. There is no statistically significant difference in drug resistance patterns between the two groups. Some progress has been made in the prevention and control of DR-TB in this area, but the effect is not very significant. There are differences in the risk factors of MDR-TB between patients with and without DM.
Identifiants
pubmed: 39123148
doi: 10.1186/s12879-024-09712-3
pii: 10.1186/s12879-024-09712-3
doi:
Substances chimiques
Antitubercular Agents
0
Types de publication
Journal Article
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
807Subventions
Organisme : Key Laboratory of Diagnosis and treatment of New and recurrent Infectious Diseases of Wenzhou
ID : No. 2021HZSY0067
Informations de copyright
© 2024. The Author(s).
Références
Naidoo K, Perumal R. Advances in tuberculosis control during the past decade. Lancet Respir Med. 2023;11(4):311–13.
doi: 10.1016/S2213-2600(23)00090-5
pubmed: 36966793
pmcid: 10036130
WHO. Global tuberculosis report 2023. In Geneva. World Health Organization; 2023.
Raviglione M, Sulis G. Tuberculosis 2015: Burden, challenges and Strategy for Control and Elimination. Infect Dis Rep. 2016;8(2):6570.
doi: 10.4081/idr.2016.6570
pubmed: 27403269
pmcid: 4927938
Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.
doi: 10.1016/j.diabres.2021.109119
pubmed: 34879977
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843.
doi: 10.1016/j.diabres.2019.107843
pubmed: 31518657
Chen X, He G, Wang S, Lin S, Chen J, Zhang W. Evaluation of whole-genome sequence method to Diagnose Resistance of 13 anti-tuberculosis drugs and characterize resistance genes in clinical Multi-drug Resistance Mycobacterium tuberculosis isolates from China. Front Microbiol. 2019;10:1741.
doi: 10.3389/fmicb.2019.01741
pubmed: 31417530
pmcid: 6685394
Yang N, Masingboon K, Samartkit N. Factors influencing diabetes self-management among adults with type 2 diabetes mellitus in China. Belitung Nurs J. 2022;8(5):389–95.
doi: 10.33546/bnj.2199
pubmed: 37554488
pmcid: 10405646
Pérez-Navarro LM, Fuentes-Domínguez FJ, Zenteno-Cuevas R. Type 2 diabetes mellitus and its influence in the development of multidrug resistance tuberculosis in patients from southeastern Mexico. J Diabetes Complications. 2015;29(1):77–82.
doi: 10.1016/j.jdiacomp.2014.09.007
pubmed: 25303784
Mi F, Jiang G, Du J, Li L, Yue W, Harries AD, et al. Is resistance to anti-tuberculosis drugs associated with type 2 diabetes mellitus? A register review in Beijing, China. Glob Health Action. 2014;7:24022.
doi: 10.3402/gha.v7.24022
pubmed: 24845213
Li B, Liu D, Wan Q, Sheng C, Wang X, Leng F, et al. Differences in treatment for Alzheimer’s disease between urban and rural areas in China. Front Neurol. 2022;13:996093.
doi: 10.3389/fneur.2022.996093
pubmed: 36247753
pmcid: 9556779
Canan A, Batra K, Saboo SS, Landay M, Kandathil A. Radiological approach to cavitary lung lesions. Postgrad Med J. 2021;97(1150):521–31.
doi: 10.1136/postgradmedj-2020-138694
pubmed: 32934178
Falzon D, Schünemann HJ, Harausz E, González-Angulo L, Lienhardt C, Jaramillo E et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017;49(3).
Xie YL, Eichberg C, Hapeela N, Nakabugo E, Anyango I, Arora K, et al. Xpert MTB/RIF Ultra versus mycobacterial growth indicator tube liquid culture for detection of Mycobacterium tuberculosis in symptomatic adults: a diagnostic accuracy study. Lancet Microbe. 2024;5(6):e520–28.
doi: 10.1016/S2666-5247(24)00001-6
pubmed: 38608680
Koh WJ, Ko Y, Kim CK, Park KS, Lee NY. Rapid diagnosis of tuberculosis and multidrug resistance using a MGIT 960 system. Ann Lab Med. 2012;32(4):264–9.
doi: 10.3343/alm.2012.32.4.264
pubmed: 22779067
pmcid: 3384807
Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson AM, et al. Risk factors, mortality, and Cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379(7):633–44.
doi: 10.1056/NEJMoa1800256
pubmed: 30110583
Xue L, Wang H, He Y, Sui M, Li H, Mei L, et al. Incidence and risk factors of diabetes mellitus in the Chinese population: a dynamic cohort study. BMJ Open. 2022;12(11):e060730.
doi: 10.1136/bmjopen-2021-060730
pubmed: 36410801
pmcid: 9680191
Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes Mellitus. Endocr Rev. 2016;37(3):278–316.
doi: 10.1210/er.2015-1137
pubmed: 27159875
pmcid: 4890267
Hamada Y, Quartagno M, Law I, Malik F, Bonsu FA, Adetifa IMO, et al. Association of diabetes, smoking, and alcohol use with subclinical-to-symptomatic spectrum of tuberculosis in 16 countries: an individual participant data meta-analysis of national tuberculosis prevalence surveys. EClinicalMedicine. 2023;63:102191.
doi: 10.1016/j.eclinm.2023.102191
pubmed: 37680950
pmcid: 10480554
McQuaid CF, Horton KC, Dean AS, Knight GM, White RG. The risk of multidrug- or rifampicin-resistance in males versus females with tuberculosis. Eur Respir J. 2020;56(3).
Gil-Santana L, Almeida-Junior JL, Oliveira CA, Hickson LS, Daltro C, Castro S, et al. Diabetes is Associated with worse clinical presentation in tuberculosis patients from Brazil: a retrospective cohort study. PLoS ONE. 2016;11(1):e0146876.
doi: 10.1371/journal.pone.0146876
pubmed: 26752596
pmcid: 4709051
Wei R, Li P, Xue Y, Liu Y, Gong W, Zhao W. Impact of diabetes Mellitus on the immunity of tuberculosis patients: a Retrospective, cross-sectional study. Risk Manag Healthc Policy. 2022;15:611–27.
doi: 10.2147/RMHP.S354377
pubmed: 35431587
pmcid: 9005360
Liu H, Wang X, Gao H, Yang C, Xie C. Physiological and pathological characteristics of vascular endothelial injury in diabetes and the regulatory mechanism of autophagy. Front Endocrinol (Lausanne). 2023;14:1191426.
doi: 10.3389/fendo.2023.1191426
pubmed: 37441493
Luciani L, Pedrelli M, Parini P. Modification of lipoprotein metabolism and function driving atherogenesis in diabetes. Atherosclerosis. 2024;394:117545.
doi: 10.1016/j.atherosclerosis.2024.117545
pubmed: 38688749
Jefferson LS, Liao WS, Peavy DE, Miller TB, Appel MC, Taylor JM. Diabetes-induced alterations in liver protein synthesis. Changes in the relative abundance of mRNAs for albumin and other plasma proteins. J Biol Chem. 1983;258(2):1369–75.
doi: 10.1016/S0021-9258(18)33203-4
pubmed: 6822503
Mohamed J, Nazratun Nafizah AH, Zariyantey AH, Budin SB. Mechanisms of Diabetes-Induced Liver damage: the role of oxidative stress and inflammation. Sultan Qaboos Univ Med J. 2016;16(2):e132–41.
doi: 10.18295/squmj.2016.16.02.002
pubmed: 27226903
pmcid: 4868511
Terán G, Li H, Catrina SB, Liu R, Brighenti S, Zheng X, et al. High glucose and carbonyl stress impair HIF-1-Regulated responses and the control of Mycobacterium tuberculosis in macrophages. mBio. 2022;13(5):e0108622.
doi: 10.1128/mbio.01086-22
pubmed: 36121152
Pan Y, Yu Y, Yi Y, Dou X, Lu J, Zhou L. The differences in drug resistance between drug-resistant tuberculosis patients with and without diabetes mellitus in northeast China: a retrospective study. BMC Infect Dis. 2023;23(1):162.
doi: 10.1186/s12879-023-08130-1
pubmed: 36922787
pmcid: 10016172
Liang D, Song Z, Liang X, Qin H, Huang L, Ye J, et al. Whole genomic analysis revealed high genetic diversity and drug-resistant characteristics of Mycobacterium tuberculosis in Guangxi, China. Infect Drug Resist. 2023;16:5021–31.
doi: 10.2147/IDR.S410828
pubmed: 37554542
pmcid: 10405913
Wu Q, Wang M, Zhang Y, Wang W, Ye TF, Liu K, et al. Epidemiological characteristics and their influencing factors among pulmonary tuberculosis patients with and without diabetes Mellitus: a Survey Study from Drug Resistance Surveillance in East China. Front Public Health. 2021;9:777000.
doi: 10.3389/fpubh.2021.777000
pubmed: 35141185
Song WM, Shao Y, Liu JY, Tao NN, Liu Y, Zhang QY, et al. Primary drug resistance among tuberculosis patients with diabetes mellitus: a retrospective study among 7223 cases in China. Infect Drug Resist. 2019;12:2397–407.
doi: 10.2147/IDR.S217044
pubmed: 31447568
pmcid: 6684854
Cheng J, Zhang H, Zhao YL, Wang LX, Chen MT. Mutual impact of diabetes Mellitus and Tuberculosis in China. Biomed Environ Sci. 2017;30(5):384–89.
pubmed: 28549496
Falzon D, Zignol M, Bastard M, Floyd K, Kasaeva T. The impact of the COVID-19 pandemic on the global tuberculosis epidemic. Front Immunol. 2023;14:1234785.
doi: 10.3389/fimmu.2023.1234785
pubmed: 37795102
pmcid: 10546619
Hutchison C, Khan MS, Yoong J, Lin X, Coker RJ. Financial barriers and coping strategies: a qualitative study of accessing multidrug-resistant tuberculosis and tuberculosis care in Yunnan, China. BMC Public Health. 2017;17(1):221.
doi: 10.1186/s12889-017-4089-y
pubmed: 28222724
pmcid: 5320743
Liang L, Wu Q, Gao L, Hao Y, Liu C, Xie Y, et al. Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China. Thorax. 2012;67(7):632–8.
doi: 10.1136/thoraxjnl-2011-200018
pubmed: 22403070
Wei SS, Gao Q, Cao YX, Han LY, Du J, Li L, et al. [A meta-analysis of risk factors for multidrug-resistant tuberculosis in China]. Zhonghua Jie He He Hu Xi Za Zhi. 2022;45(12):1221–30.
pubmed: 36480854
Shin HJ, Yoon JY, Na YO, Lee JK, Kho BG, Kim TO, et al. Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment. PLoS ONE. 2023;18(11):e0294490.
doi: 10.1371/journal.pone.0294490
pubmed: 37972037
pmcid: 10653473
Thumamo Pokam BD, Enoh JE, Eyo AO, Umoh NO, Guemdjom PW. Uric acid levels in patients on antituberculosis drugs in the southwest region of Cameroon. Int J Mycobacteriol. 2018;7(1):89–91.
doi: 10.4103/ijmy.ijmy_161_17
pubmed: 29516892
O’Keeffe DT, Maraka S, Rizza RA. HbA1c in the evaluation of diabetes Mellitus. JAMA. 2016;315(6):605–6.
doi: 10.1001/jama.2015.16561
pubmed: 26864415
Li S, Liang Y, Hu X. Risk factors for multidrug resistance in tuberculosis patients with diabetes mellitus. BMC Infect Dis. 2022;22(1):835.
doi: 10.1186/s12879-022-07831-3
pubmed: 36369020
pmcid: 9650799
Lyu M, Wang D, Zhao J, Yang Z, Chong W, Zhao Z, et al. A novel risk factor for predicting anti-tuberculosis drug resistance in patients with tuberculosis complicated with type 2 diabetes mellitus. Int J Infect Dis. 2020;97:69–77.
doi: 10.1016/j.ijid.2020.05.080
pubmed: 32474202
Duque A, Lin SY, Desmond E, Rienthong S, Rienthong D, Boonin C. Evaluation of the BD Bactec MGIT 320 system for detection of mycobacteria and drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol. 2013;51(10):3403–5.
doi: 10.1128/JCM.01357-13
pubmed: 23863564
pmcid: 3811643